Prescribing information

 

About the MayzentConnect programme.

 

Dedicated patient support

MayzentConnect offers dedicated support to patients with secondary progressive multiple sclerosis (SPMS) with active disease and healthcare professionals throughout the MAYZENT journey. Novartis Pharmaceuticals gives those who enrol in the programme unique access to a wide range of services, including specialised medical testing and an experienced nurse team. The programme recognises that multiple sclerosis (MS) services and patients with SPMS with active disease have unique needs and is designed to offer personalised support in conjunction with the usual medical care given by your hospital’s MS team.

MayzentConnect is provided to you as a Package Deal, on behalf of Novartis Pharmaceuticals UK Limited.

 

Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.1

MS, multiple sclerosis; SPMS, secondary progressive multiple sclerosis.

Reference

  1. MAYZENT (siponimod) Summary of Product Characteristics.
     
SIP20-C001f May 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]